Limited to clinical investigational use    
   
  www.myelostat.com
   
 
 
  Site map
   
  links

Myelostat® homepage

About Myelostat® (hemi-synthetic homoharringtonine) Stragen

Mechanism of action of homoharringtonine

Clinical trials about Myelostat®

Phase I-II trial to asses the dose limiting toxicity, tolerance and efficacy of hemi-synthetic homoharringtonine (Myelostat®) in combination with imatinib mesylate (Glivec®) in patients with chronic myeloid leukemia after cytogenetic failure with Glivec®.

A phase II multicentre, single-arm, open-label study of subcutaneous hemi-synthetic homoharringtonine (HHT) alone in patients with accelerated phase chronic myeloid leukemia (CML) who are refractory to, or have relapsed on imatinib mesylate

Published articles & abstracts about Myelostat®

Myelostat® (Hemi-synthetic Homoharringtonine) Bibliography

Etude clinique et pharmacocinétique de phase I-II utilisant l'homoharringtonine hemi-synthétique (HHT, Myélostat®) chez des patients avec leucémie aiguë myéloïde (LAM) en rechute ou réfractaires.

Homoharringtonine in Combination with Imatinib for Patients with CML Who have Achieved Partial or Complete Cytogenetic Responses.

Natural Homoharringtonine Bibliography

Regulatory Status for Myelostat® (homoharringtonine) Stragen


Stragen Homepage

              => www.stragen.ch

Other informations about Myelostat®

              => Myelostat® (Homoharringtonine) Stragen


Alias : www.homoharringtonine.com
   
 
 
Design by
VISTA MULTIMEDIA | Geneva - Switzerland

vista@vistamultimedia.ch
   
 
 
   
© 2004 Stragen - All rights reserved


Disclaimer :

Myelostat.com is an international website for Myelostat® (Hemi-synthetic Homoharringtonine Stragen) and the information on this website is not country-specific and may contain information that is outside the approved indications in the country in which you are located. You may print information from this website only for non-commercial personal use. You must retain and reproduce each and every copyright notice or other proprietary rights notice contained in any information you print. You may not, however, distribute, modify, transmit, reuse, repost, or use the content of the Site for public or commercial purposes, including the texte, images, audio, and video without written permission of Stragen Pharma SA. You should assume that everything you print from this website is copyrighted unless otherwise noted and may not be used except as provided in the Terms and Conditions or in the texte on the website. Stragen Pharma SA neither warrants nor represents that your use of materials displayed on the Site will not infringe rights of third parties not owned by or affiliated with Stragen Pharma SA. While Stragen Pharma SA uses reasonable efforts to include accurate and up to date information in the website, Stragen Pharma SA makes no warranties or representations with respect to the content of the website, which is provided "as is". Stragen Pharma SA accepts no responsibility or liability whatsoever arising from or in any way connected with the use of this website or its content. In particular, Stragen Pharma SA will not be liable for the accuracy, completeness, adequacy, timeliness, or comprehensiveness of the information contained on this website. Some jurisdictions do not allow the exclusion of implied warranties, so the above exclusion may not apply to you. The information printed from this website may contain technical inaccuracies or typographical errors. Stragen Pharma SA reserves the right to make changes, corrections and/or improvements to this information, and to the products and programs described in such information, at any time without notice.